1. Explain the standards used by the Food and Drug Administration to make bioequivalency assessments;
2. Discuss factors that affect drug bioavailability;
3. Describe potential therapeutic effects when multisource drugs are interchanged;
4. Identify drugs and classes of drugs that require special scrutiny when generic interchange is considered; and,
5. Describe legal ramifications of inappropriate drug substitution.

The author, sponsor, and publisher of this continuing education program have made all reasonable efforts to ensure that all information contained herein is accurate in accordance with the latest available scientific knowledge at the time of acceptance for publication. However, because information regarding drugs (their administration, dosages, contraindications, adverse reactions, interactions, special warnings, precautions, etc.) is subject to constant change, the reader is advised to check the manufacturer's package insert for information concerning recommended dosages and potential problems and cautions prior to dispensing or administering the drug. Special precautions should be taken when a drug is new, or highly toxic, or is unfamiliar to the dispenser or administrant. This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the FDA. Neither the publisher nor sponsor promotes the use of any agent outside of approved labeling. Statements made in this monograph have not been evaluated by the Food and Drug Administration. Nutritional products discussed are not intended for the diagnosis, treatment, cure, or prevention of any disease.